Reports
Generics gaining ground in French pharmaceutical market
The French pharmaceutical market is forecast to grow by a miniscule amount in the coming years due to the growing influence of generics in the country.
US pay-for-delay deals decrease in 2013
During 2013, companies filed a total of 145 final patent dispute settlements, of which 29 were potentially anticompetitive or ‘pay-for-delay’ agreements between brand-name and generics companies, according to a new report released on 22 December 2014 by the US Federal Trade Commission (FTC).
Generics still cost more in Canada, but prices decreasing
A report issued in December 2014 by Canada’s Patented Medicine Prices Review Board (PMPRB) finds that the prices of generics in Canada have decreased significantly in recent years. However, Canadians are still paying more for their generics than patients in many other countries.
EU problematic patent settlements stabilize
The number of patent settlements between originator and generics companies concluded during 2013 has reduced compared to 2012. While the number of problematic or so-called ‘pay-for-delay’ deals have stabilized compared to 2012.
UK uses less brand-name medicines per person
The UK uses fewer brand-name medicines per person than many other countries, but this means that the country tends to use older medicines rather than the latest ones, according to a new report.
Generics makers challenging more patents
In recent years generics makers are becoming bolder and challenging more patents on originator drugs. In fact, litigation regarding patents on pharmaceuticals is on the rise, particularly when it comes to newer drugs.
Generics and biosimilars contribute to European drug savings
As governments around the world try to rein in healthcare expenses, generics and biosimilars can play a major role in reducing this budgetary burden [1, 2].
Growth in Netherlands pharma market held back by generics policies
The pharmaceutical market in The Netherlands will rise slowly from approximately US$6.7 billion in 2014 to US$7.2 billion by 2020. Growth is being restricted by the government’s focus on generics as a cost-containment tool, according to research and consulting firm GlobalData.
Biosimilars use in Europe varies widely
Use of biosimilars in Europe varies widely between countries and therapy areas, according to a report published by IMS Health in October 2014.
Development of biosimilars for rheumatoid arthritis
Biosimilars development is a hive of activity, with development of biosimilars for the treatment of rheumatoid arthritis being one of the busiest areas in the biosimilars field, see Table 1 [1].
